دورية أكاديمية

Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.

التفاصيل البيبلوغرافية
العنوان: Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy.
المؤلفون: Cormier JN; Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA., Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL
المصدر: Journal of immunotherapy (Hagerstown, Md. : 1997) [J Immunother] 1998 Jan; Vol. 21 (1), pp. 27-31.
نوع المنشور: Comparative Study; Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 9706083 Publication Model: Print Cited Medium: Print ISSN: 1524-9557 (Print) Linking ISSN: 15249557 NLM ISO Abbreviation: J Immunother Subsets: MEDLINE
أسماء مطبوعة: Publication: Hagerstown, MD : Lippincott Williams & Wilkins
Original Publication: Hagerstown, MD : Lippincott-Raven, c1997-
مواضيع طبية MeSH: Immunotherapy*, Antigens, Neoplasm/*analysis , Melanoma/*immunology , Membrane Glycoproteins/*analysis , Monophenol Monooxygenase/*analysis , Neoplasm Proteins/*analysis, CD4-Positive T-Lymphocytes/immunology ; CD8-Positive T-Lymphocytes/immunology ; Humans ; MART-1 Antigen ; Melanoma/therapy ; Neoplasm Metastasis ; gp100 Melanoma Antigen
مستخلص: A variety of human melanoma-associated antigens (MAA) have been identified that can be recognized by T lymphocytes in a major histocompatibility complex-restricted fashion. Among them, tyrosinase, MART-1/Melan- A, and gp100 are derived from nonmutated melanocyte lineage-specific antigens (Ag). These Ag can be recognized by CD8+ and, in the case of tyrosinase, CD4+ T cells. The in situ expression of these MAA may be a significant cofactor in determining the recognition of melanoma targets by Ag-specific T cells. In this study, we examined the patterns of expression of these MAA using immunohistochemical methods on 30 metastatic tumor deposits derived from 25 patients. MAA expression was heterogeneous among the 30 specimens and also within individual lesions. Of note, 23% of the samples examined failed to express the gp100 protein, and 17% of samples had no detectable expression of MART-1. In contrast, all lesions demonstrated some degree of tyrosinase expression even in cases where both gp100 and MART-1 were not detectable. In addition, 60% of samples (18 of 30) showed strong positivity for tyrosinase (> 75% of cells staining) compared with 40% for gp100 and 36% for MART-1. Currently, a number of experimental immunotherapies for melanoma are directed against the MAA tyrosinase, MART-1, and gp100. Although threshold levels of Ag required for T-cell recognition have not yet been defined, tumor-associated Ag expressed in high density, such as tyrosinase, may be better targets for future immunotherapy trials.
المشرفين على المادة: 0 (Antigens, Neoplasm)
0 (MART-1 Antigen)
0 (MLANA protein, human)
0 (Membrane Glycoproteins)
0 (Neoplasm Proteins)
0 (PMEL protein, human)
0 (gp100 Melanoma Antigen)
EC 1.14.18.1 (Monophenol Monooxygenase)
تواريخ الأحداث: Date Created: 19980211 Date Completed: 19980226 Latest Revision: 20191102
رمز التحديث: 20231215
DOI: 10.1097/00002371-199801000-00003
PMID: 9456433
قاعدة البيانات: MEDLINE